$364 Million is the total value of Tri Locum Partners LP's 41 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BIIB | New | BIOGEN INC | $24,177,000 | – | 90,551 | +100.0% | 6.64% | – |
| NBIX | New | NEUROCRINE BIOSCIENCES INC | $20,859,000 | – | 196,390 | +100.0% | 5.72% | – |
| REGN | New | REGENERON PHARMACEUTICALS | $20,745,000 | – | 30,115 | +100.0% | 5.69% | – |
| SAVA | New | CASSAVA SCIENCES INCcall | $12,099,000 | – | 289,300 | +100.0% | 3.32% | – |
| GSK | New | GSK PLCsponsored adr | $12,052,000 | – | 409,503 | +100.0% | 3.31% | – |
| New | BAUSCH PLUS LOMB CORP | $10,746,000 | – | 700,525 | +100.0% | 2.95% | – | |
| MRTX | New | MIRATI THERAPEUTICS INC | $10,583,000 | – | 151,534 | +100.0% | 2.90% | – |
| SRPT | New | SAREPTA THERAPEUTICS INC | $10,550,000 | – | 95,445 | +100.0% | 2.90% | – |
| MRVI | New | MARAVAI LIFESCIENCES HLDGS I | $7,169,000 | – | 280,811 | +100.0% | 1.97% | – |
| AKRO | New | AKERO THERAPEUTICS INC | $7,125,000 | – | 209,248 | +100.0% | 1.96% | – |
| New | ASTRIA THERAPEUTICS INC | $5,709,000 | – | 631,579 | +100.0% | 1.57% | – | |
| NTRA | New | NATERA INC | $5,695,000 | – | 129,955 | +100.0% | 1.56% | – |
| TEVA | New | TEVA PHARMACEUTICAL INDS LTDsponsored ads | $5,517,000 | – | 683,613 | +100.0% | 1.51% | – |
| New | VENTYX BIOSCIENCES INC | $4,364,000 | – | 125,000 | +100.0% | 1.20% | – | |
| ISEE | New | IVERIC BIO INC | $3,419,000 | – | 190,597 | +100.0% | 0.94% | – |
| BEAM | New | BEAM THERAPEUTICS INC | $2,561,000 | – | 53,754 | +100.0% | 0.70% | – |
| CRSP | New | CRISPR THERAPEUTICS AGnamen akt | $2,383,000 | – | 36,460 | +100.0% | 0.65% | – |
| PCVX | New | VAXCYTE INC | $1,906,000 | – | 79,411 | +100.0% | 0.52% | – |
| FGEN | New | FIBROGEN INC | $967,000 | – | 74,348 | +100.0% | 0.26% | – |
| New | ARCELLX INC | $804,000 | – | 42,826 | +100.0% | 0.22% | – | |
| LPTX | New | LEAP THERAPEUTICS INC | $626,000 | – | 711,798 | +100.0% | 0.17% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| FEMASYS INC | 10 | Q3 2023 | 0.5% |
| REGENERON PHARMACEUTICALS | 9 | Q3 2023 | 13.8% |
| LILLY ELI & CO | 9 | Q2 2023 | 9.5% |
| X4 PHARMACEUTICALS INC | 8 | Q3 2023 | 3.0% |
| XENON PHARMACEUTICALS INC | 8 | Q3 2023 | 2.4% |
| ARGENX SE | 7 | Q3 2023 | 12.8% |
| STEVANATO GROUP S P A | 7 | Q2 2023 | 5.8% |
| PROTAGONIST THERAPEUTICS INC | 7 | Q2 2023 | 7.1% |
| AVADEL PHARMACEUTICALS PLC | 7 | Q3 2023 | 6.4% |
| BELLUS HEALTH INC NEW | 7 | Q3 2022 | 4.3% |
View Tri Locum Partners LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G | 2023-04-27 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
View Tri Locum Partners LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.